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SUMMARY 
• The ABH blood group determinants are 
carbohydrates found in different human cells 
and tissues. The modulation in their expression 
in the course of ontogenesis, as well as the 
studies on their subcellular localization, impose 
a discussion on the role of ABH antigens as 
molecules participating in cell interactions, con- 
tact inhibition, adhesion and metastases. It is 
supposed that they are also involved in cellular 
differentiation during human embryogenesis. The 
described association between blood groups and 
disease and the de novo acquisition of blood 
group determinants support the idea that ABH 
antigens are related to pathological processes. 
The modulation in blood group antigen expres- 
sion observed in several tumors demands a clari- 
fication of their diagnostic and prognostic value 
as tumor-associated markers. 
INTRODUCTION 
• The ABH blood group determinants are oli- 
gosaccharides bound to different human glycolipids 
and glycoproteins. Although they are discovered in 
the very beginning of the century (K.Landsteiner, 
1901) and their biochemistry is already well de- 
fined, the biological functions of blood group anti- 
gens (BGA) are still obscure. Only the role of red 
blood cell antigens in blood typing, haemotransfu- 
sions and organs transplantations is specified for the 
present. 
The recent interest in carbohydrate molecules, and 
in BGA in particular, impose a discussion on the 
participation of these structures in cell interactions 
(1). It is supposed that ABH antigens play an essen- 
tial role in the differentiation of normal cell (2,3). 
There is evidence supporting the contribution of 
BGA to cell membrane rigidity and to cell's interac- 
tion with its surrounding (1). It is also believed that 
AB H determinants are involved in intercellular con- 
tacts. The molecules engaged in these processes 
have common biochemical structure with BGA, so 
that it is quite possible ABH antigens to participate 
in the complex cell interactions (2,4-6). 
The cytological expression of BGA is a dynamic 
phenomenon. Each cell can easily change its 
glycosilation (6). The alterations in ABH antigen 
expression accompanying cell growth and matura- 
tion are especially important. The interactions be- 
tween glycoconjugates taking part in the regulation 
of cell growth are not clear enough. Two possible 
mechanisms are discussed: contact inhibition or 
interaction with cell surface receptor proteins (7). 
The gradual elongation and arborization of BGA 
observed in the course of cell differentiation is 
modified in anaplastic cells (8). It is believed that 
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antigenic modulation in tumor cells could reflect the 
degree of their malignancy (9,10). The hypothesis 
for the paraembry onal character of tumor cells gives 
reasons a correlation between EGA expression and 
oncogenesis to be searched (11). The possibilities 
B G A to be included in the list of the stage-dependent 
and oncofoetal antigens and to be regarded as diag- 
nostic and prognostic markers for the clinical out- 
come of malignant diseases are also discussed (12). 
These suggestions could be supported by the rela- 
tionship between the decreased number of EGA 
determinants and the loss of contact inhibition dis- 
covered in vitro (2). This in turn could facilitate 
tumor invasion and metastases. 
GENETICS AMD BIOCHEMISTRY OF ABH BGA 
• The molecules determining the erythrocyte 
EG-specificity are glycosphingolipids, while EGA 
in epithelial cells are water-soluble glycoproteins 
(8). Both types of macromolecules contain a com- 
mon oligosaccharide chain, but the antigenic speci- 
ficity is defined by the so called immunodominant 
sugar residues: L-fucose (determining H-specific- 
ity), N-acetyl-galactosamin (A) and D-galactose 
(B) (13). Their sequential addition to one of the six 
precursor backbone chains leads to the formation of 
ABH BGA (Fig. 1) (14). 
The synthesis and expression of ABH BGA are 
regulated by three independent gene loci: ABH 
 
situated in chromosome 9p34, Hh and Sese - in 
chromosome 19 (8). It is known that the transferase 
enzymes but not the ABH antigens themselves are 
the primary gene products (8). BGA genes encode 
three glycosyltransferases: (i) 1-2-fucosyltrans- 
ferase responsible for the synthesis of antigen H; (ii) 
N-acetyl-galactosylransferase responsible for the 
synthesis of antigen A, and (iii) D-galacto- 
sylransferase responsible for the synthesis of anti- 
gen B (13-16). Because of the multistep biosynthe- 
sis the loss in the enzymes results in the disappear- 
ance of the antigen it is responsible for. 
According to the model of Oriol et al. (17) the genes 
Hh and Sese are closely linked and located in chro- 
mosome 19. They encode two-1-2-fucosyl-trans- 
ferases with different biochemical activity and tis- 
sue localization (18). It is supposed that some epi- 
static interactions leading to variations in ABH 
antigen expression intensity cannot be neglected 
either (19). 
CELLULAR AMD TISSUE EXPRESSION OF 
ABH BGA 
• Phylogenetic studies indicate that BGA have 
first occurred in tissues, but not on red blood cells 
(20). ABH antigens are discovered in ectodermal 
and endodermal epithelial cells of lower mammals 
whose erythrocytes are entirely lacking BGA. Even 
the baboons expressing ABH antigens in their vas- 
cular endothelium are negative for red blood cell 
ABH antigens. Erythrocytes are in fact evolutionary 
the latest cells that have acquired ABH BGA. Only 
the humans and some primates possess red blood 
cell ABH antigens (20,21). 
The scanning electron microscopy on human eryth- 
rocytes reveal that the number and density of anti- 
genic determinants is different in the particular red 
blood cell subgroups, as well as on the convex and 
concave part of the cell (22). The flow cytometric 
analyses reveal the presence of nonsymetric (non- 
Gaucian) distribution of A-epitopes among the eryth- 
rocyte population of every single person (23). It is 
supposed that this heterogeneity is due to intrinsing 
differences in the quantity of antigen A or to 
variations in glycosyltransferase activity. The exact 
reason for these variations is not yet known. 
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Figure 1. Precursor chains for the biosynthesis 
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The tissue expression of ABH BGA depends on the 
combined influence of the genetic determination, 
the embryological origin and the cell differentiation 
(Fig.2) (24). 
In the tissues and organs with ectodermal origin 
BGA are discovered in cells of basal and spinous 
epidermal layers, in the hair follicles, oral mucosa, 
and lobular and ductal zones of the mammary gland 
(25,26). In the endodermal derivates, ABH antigens 
are found in stomach, bile duct and bladder epithe- 
lial cells (12,25). From the mesodermal derivates 
only the endometrium expresses BGA in accor- 
dance with the secretory status of the uterus. 
There are some cells that do not express ABH 
antigens during human ontogenesis. Such are the 
osteocytes, myocytes, thymocytes, thyroid epithe- 
lial cells, splenocytes and hepatocytes (25,26). It is 
not clear whether these cells do not possess or have 
lost the ability to produce BGA. - 
BGA AMD ASSOCIATION WITH DISEASE 
• The association between the ABH BGA pheno- 
type and the genetic predisposition towards some 
diseases is still a debatable issue. Aird at al (27) were 
the first to announce the positive correlation be- 
tween the higher frequency of antigen A and the 
stomach carcinoma. Higher morbidity rate of pan- 
creatic carcinoma is recorded in patients with A 
blood group as compared to B and O (28). Some 
researchers report prevalence of A blood group- 
bearing women suffering from breast cancer (29), 
while others do not establish such correlation (30). 
The information concerning the leukaemia morbid- 
ity is quite controversial. Patients with B and AB 
phenotypes predominate in acute leukemia, but 
pantients with lymphocytic leukaemia are more 
common in O blood group individuals (31). Ameri- 
can investigators notify of higher frequency of 
Hodgkin's disease in B blood group patients (32), 
while English researchers do not find any depen- 
dence (33). Australian scientists reportlower frequency 
of Ax phenotypes and higher of A2 in leukemic patients 
(34). 
There are no definite conclusions about the blood 
groups-disease links, as well as satisfactory expla- 
nation of the correlations observed by some authors. 
It is possible that populational variations in blood 
group phenotype distribution, and/or biochemical 
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individuals possessing a particular allele to have 
higher predisposition to some diseases. For ex- 
ample, people with allele A2 are more susceptible to 
leukaemia as compared to those not possessing it 
(34). An enzyme defect in EGA biosynthesis could 
be a possible explanation. It is not clear whether the 
changes in the frequency of ABH antigens are the 
reason or the result for development of pathologic 
processes. 
BGA ACQUIRED DE HOVO 
• In infectious and malignant diseases an acqui- 
sition of BGA-like substances is observed. Usually 
"demasking" of the so called "crypt" antigens (built 
of carbohydrate residues mainly) takes place. When 
the last sugar residue is removed from the backbone 
chain, the last but one is exposed, thus leading to the 
appearance of a new antigen. Crypt antigen 
demasking is usually a result of glycosylytic degra- 
dation on membrane oligosaccharides caused by 
bacterial enzymes. A similar phenomenon is often 
observed in gut and lung infections. In the course of 
intestinal inflammatory diseases, the so called "ac- 
quired B status" is manifested in some patients 
having Aj genotype (35,36). It is supposed that a 
membrane absorption of B antigen-like substances 
by E. coli 086 and P. vulgaris on A and O blood group 
cells is concerned. 
ABH BGA AMD CELL INTERACTIONS 
• The presence of specific oligosaccharide anti- 
gens on cell membranes and in extracellular matri- 
ces during embryogenesis and cell differentiation 
impose a discussion on the possibility such carbohy- 
drate antigens to play the role of "recognition" 
structures for several proteins (37). 
The immunodominant sugar of the stage-dependent 
embryonic antigen SSEA-1 found on the cell surface 
of 8 days old mice embryos is composed of the 
monofucosylated isomer, known as antigen Lewis
x
. 
SSEA-1 participates in the earliest processes of 
embryonic cell adhesion (18,38, see also the paper 
of Marani reviwed CD 15, this issue of Biomed Rev, 
pages 1-9). The variations in the duration of SSEA- 
1 antigen expression prompt that it could serve as a 
ligand for receptors engaged in this process. The 
studies on SSEA-1, lymphocyte antigens and on 
BGA suggest that ABH antigens on human 
leucocytes act as ligands for cell adhesion mol- 
ecules (18). These data put forward the questions for 
the biological functions of the oligosaccharide rep- 
ertoire. The first carbohydrate antigens discovered 
are characterized on the molecular level as ligands 
for E-selectin involved in inflammation (18). The 
biological specificity is manifested by cytokine regu- 
lated expression of carbohydrate-linking proteins on 
endothelial cell membranes. It is already accepted 
that biological specificity could originate from the 
binding of a particular protein to oligosaccharide 
structures that are not unique but a part of the cell 
type-specific repertoire (38). 
The experiments aimed at clarifying the molecular 
basis of mammalian fertilization show that a BGA- 
like specific oligosaccharide is situated in mouse 
zona pellucida, i.e. glycoprotein-3 that is respon- 
sible for the sperm binding (39). On the other hand, 
oc-D-galactosyltranferase with molecular weight 
similar to that of the zona pellucida glycoprotein-3 
is found on sperms (40). It is assumed that different 
adhesion mechanisms facilitate the con tact between 
egg and sperm. Obviously carbohydrate structures 
play an important role in this process. 
Studies on the function of epidermal growth factor 
receptor (EGF-R) reveal that ABH antigens are 
related to this protein and they could possibly par- 
ticipate in the EGF binding, as well as in the signal 
cascade triggered by the EGF itself (41). 
The glycolipids and the glycoproteins bound to 
BGA oligosaccharide chains are situated on the 
extracellular part of the cell membrane. The partici- 
pation of membrane-bound sugar residues in the 
adhesion of different cell types in the vascular 
system is a well known phenomenon. P- and E- 
selectins meditate the adhesion of endothelial cells 
to leukocytes. The presence of ABH BGA on plate- 
let adhesion glycoproteins focuses on the role of 
B GA in the recognition between platelets and endot- 
helial cells, as well as on the association between 
blood groups and cardiovascular pathology (9). It is 
established that people with blood group A show a 
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higher risk of thrombosis and cardiac diseases (42). 
Thus, the supposed EGA-influenced modulation of 
cell adhesion mechanisms is an issue demanding 
further research in cardiovascular medicine. 
The investigations on the subcellular localization of 
EGA further contribute to the clarification of their 
participation in cell interactions. Immunoelectron 
microscopic studies on human foetal thymus reveal 
the presence of EGA A in the zones of desmosomal 
contacts, as well as antigen clustering on lympho- 
cyte membranes in close proximity to epithelial 
cells and macrophages (unpublished results). 
The experiments with lectins having EGA specific- 
ity demonstrate that ABH antigens could be re- 
garded as recognition sites for the stimulation of 
Ca
2+
 and Cl' ion transports (4). The activation of ion 
transport through the cell membrane is often linked 
with the proliferative and mitogenic effect of some 
lectins and growth factors. Any modifications in 
ABH antigen structure could possibly lead to changes 
in cell proliferation. They in turn could either favour 
or hamper the interactions between cells, growth 
factors, and endogenous lectins. 
It is suspected that BGA could function as signal 
molecules in cell interactions (43). The information 
exchange between neighbouring cells is extremely 
important for their proliferation and differentiation 
both in vitro and in vivo (43). 
ABH BGA AND CELL DIFFEREMTIATIOM 
M The informative function of cell membrane 
carbohydrates has probably evolved later on as 
multicellular organisms developed. Koscielak (44) 
considers that BGA undergo changes connected 
with cell differentiation and maturation. Cell migra- 
tion is known to be a common event in the course of 
the embryogenesis of all vertebrates. Obviously the 
cells participating in this process possess inert BGA 
preventing their interaction with lectins, adhesion 
and aggregation factors. Once settled in their new 
surrounding, the cells gradually differentiate and ac- 
quire novel specific and active membrane determinants. 
Some authors describe the expression of ABH BGA 
in embryonic mesenchyme cells even before their 
transformation into endothelial ones (unpublished 
results). They believe that the presence of BGA in 
the still undifferentiated mesenchyme could be 
regarded as an early immunocytologic marker for 
potential endothelial differentiation. 
Another fact confirming the thesis for the role of 
BGA in cell differentiation is the increasing gradi- 
ent of ABH antigen accumulation towards the 
corneous layer in both embryonic and adult nor- 
mal epidermis (3,26). 
Examining erythrocytes of foetuses, newborns 
and healthy adults, Watanabe and Hakomori (45) 
establish large amounts of antigen H in adult cells 
(45). The foetal and newborn erythrocytes entirely 
lack the antigen or it is in minimal quantities. Lots 
of precursor chains are discovered in prenatal 
cells. The postnatal changes in the agglutinability 
of human red blood cells is now explained with the 
arborization of oligosaccharide chains, a process 
parallel to cell differentiation. The lower aggluti- 
nation activity of foetal erythrocytes could be due 
to the lack of branched A and B antigens which 
could be accepted as markers of differentiation. 
ABH BGA AMD TUMORS 
M The investigations on BGA expression in 
the course of human ontogenesis and oncogenesis 
give grounds to some authors to consider BGA as 
"stage-dependent, oncofoetal or tumor-associated 
antigens" (1,2,46). Szulman's studies show that 
there is a stage-dependency in the tissue expres- 
sion of ABH antigens (47). It is most obvious in the 
distal colon where BGA are present up to the 10- 
14-th weeks of gestation; afteron they disappear 
and miss during the whole postnatal life. They 
reappear when malignant transformation in the 
same region begins (3,47,48). It is supposed that 
contiguous processes of repression and derepres- 
sion of the glycosyltransferase genes occurs. Ac- 
cording to Manzo's hypothesis for the 
paraembryonal character of malignant cells (11), 
tumor cells acquire the ability to express embry- 
onic features and traits. It is likely that the expres- 
sion of BGA, typical of the prenatal period, to be   
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sion of EGA, typical of the prenatal period, to be one 
of these characteristics. 
Four different types of changes in BGA expression 
are recorded in tumor cells: (i) antigen loss; (ii) 
enhanced synthesis or neoexpression; (iii) BGA 
expression incompatible with the blood group of the 
person, and (iv) changes in the cellular localization 
of ABH antigens, from cell surface to cytoplasm 
(1,2,12,48). 
The neoplasms of breast, urinary bladder and pros- 
tatic gland are characterized with antigen loss 
(3,12,48). Some researchers do not find any correla- 
tion between the antigen deletion and the clinical 
course of the disease. Others claim that the higher 
the antigen loss, the worse the patient's prognosis 
(bladder and lung carcinomas especially) (2). It is 
supposed that BGA deletion disturbs cell's "orienta- 
tion" in its microenvironment. If so, the hampered 
contact inhibition enforces the cells to begin invad- 
ing and metastazing (1). 
Enhanced BGA synthesis is observed in stomach 
tumors and primary hepatocellular carcinomas 
(25,48). The foetal and adult normal hepatocytes 
lack BGA, but the malignant ones can express ABH 
antigens. This could be possibly due to derepression 
of glycosyltransferase genes. Itis notknown whether 
this genetic alteration is a cause or a consequence of 
neoplastic transformation. 
The tissue expression of incompatible BGA is 
explained with defective antigen biosynthesis.The 
insufficient glycosyltransferase activity can result 
in misproduction of oligosaccharide chains. There 
also could be normal enzyme activity but lack of 
precursor molecules that in turn leads to antigen 
loss. Another possible explanation could be pres- 
ence of normal BGA synthesis accompanied by 
enhanced glycosylytic degradation. 
The changes in the cellular localization of BGA in 
tumor cells could reflect the deletion of molecules 
participating in cell contacts. So, an increased 
invasive and metastatic potential is observed. The 
scanty and contradictory parallel studies on BGA 
expression in the primary tumors and in their 
metastases put forward the discussion on the de- 
creased intensity of antigen expression in the pri- 
mary tumor as a reflection of initial anaplasia (2). 
COMCLUSION 
Carbohydrate structures, and BGA in particu- 
lar, focus the current interest of many scientists 
because of the modulations in their expression. 
Although complex immunobiological functions need 
further elucidation, recent knowledge in 
glycoimmunology suggests that ABH BGA are in- 
volved in cell differentiation, cell interactions, 
oncogenesis, and predisposition to several diseases. 
The efforts are now aimed at the diagnosis, progno- 
sis and control of the clinical and biological charac- 
teristics of these processes through monitoring B GA 
expression. 
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